PhageLab Raises US$3.5M led by Kaszek Ventures to Expand Biotech Solutions for the Supply Chain
PhageLab raised over US$3.5 million in a convertible note financing round with investor participation from Kaszek Ventures, reinforcing its position within Chile’s biotechnology and innovation ecosystem.
Phage Lab continues to consolidate its position within Latin America’s biotechnology ecosystem after securing more than US$3.5 million in a new financing round structured through convertible notes, with the participation of prominent regional and international investors.
Financing round highlights investor confidence
The Chilean biotechnology company raised over US$3.5 million through a convertible note structure, attracting high-profile investors, including Kaszek Ventures.
The transaction reflects PhageLab’s capacity to secure capital across successive funding rounds, reinforcing its role as a leading developer of biotechnology solutions aimed at improving efficiency and resilience across the supply chain.
According to Chilean law firm Carey, which advised PhageLab throughout the process, the deal underscores sustained investor confidence in the company’s growth strategy and technological capabilities.
Legal structuring and international standards
Carey provided legal counsel to PhageLab in the negotiation and preparation of the documentation for the financing round. The firm also advised on the international structuring of the transaction, ensuring efficient execution and alignment with global legal and regulatory standards.
“The investment strengthens Chile’s innovation ecosystem and positions PhageLab as a key player in regional biotechnology,” Carey stated.
The legal team from Carey was led by partner Francisco Guzmán, with associate Andrés Latorre supporting the transaction.
Counsel representing investors and counterparties
On the investor side, law firm Tanoira Cassagne acted as legal counsel to The Yield Lab. The advisory team was led by partner Eugenia Martínez Gualco.
Meanwhile, Portaluppi Guzmán & Bezanilla served as counsel to the counterparty, with the team led by partner Eugenio Guzmán Gatica.
Strengthening Chile’s biotech ecosystem
This transaction further highlights Chile’s growing relevance as a hub for biotechnology innovation in the region.
By successfully closing a financing round with international participation and robust legal structuring, PhageLab reinforces its standing as a company capable of scaling biotech solutions while contributing to the broader development of the country’s innovation and investment ecosystem.
